Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

Ongoing Phase 1b/2 Trial of the Allosteric MEK1/2 Inhibitor REC-4881 as Monotherapy (FAP): Updated Safety and Efficacy Najat Khan, Ph.D ., Chief R&D and Chief Commercial Officer and incoming CEO and ...

Two important architectures are Artificial Neural Networks and Long Short-Term Memory networks. LSTM networks are especially ...

Instead of a single, massive LLM, Nvidia's new 'orchestration' paradigm uses a small model to intelligently delegate tasks to ...

Telling ChatGPT to fact-check a random answer before solving an actual problem makes it think harder, and get the answer right more often – even if the earlier 'random' answer has nothing to do with ...

Famed GTA developer Dan Houser said models trained on synthetic data could degrade game quality as creators rapidly adopt AI ...

At Industrial Wireless Forum, industry leaders explored how agentic AI running on private 5G is transforming factories and plants.

Artificial intelligence and machine learning are reshaping how investors build and maintain portfolios. These tools bring ...

PageRank interpreted hyperlinks as endorsements, prioritizing pages linked by many others and weighting endorsements from ...

Environmental Engel curves characterize the relationship between the embodied environmental impact of household consumption ...

Yet too many CEOs still believe they can solve the problem by outbidding competitors for scarce talent. They can’t. The AI skills gap isn’t a hiring problem. It’s a systems problem.

In the evolving landscape of artificial intelligence (AI), the assumption that more data lead to better models has driven unchecked reliance on synthetic data to augment training datasets. Although ...